ストックスクリーナーアプリを入手
7.67
1.67%
-0.13
アフターアワーズ：
7.48
-0.19
-2.48%
前日終値:
$7.80
開ける：
$7.64
24時間の取引高:
941.65K
Relative Volume:
0.83
時価総額：
$414.48M
収益：
$2.22M
当期純損益:
$-40.51M
株価収益率:
-5.9703
EPS:
-1.2847
ネットキャッシュフロー:
$-46.53M
1週間 パフォーマンス:
-2.91%
1か月 パフォーマンス:
-70.50%
6か月 パフォーマンス:
-61.59%
1年 パフォーマンス:
-9.45%
1日の値動き範囲:
$7.40
$7.78
1週間の範囲:
$7.25
$8.07
52週間の値動き範囲:
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
7.67 | 421.50M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Mizuho | Outperform |
| 2025-11-18 | 開始されました | Evercore ISI | Outperform |
| 2025-10-14 | 開始されました | Truist | Buy |
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | Piper Sandler | Overweight |
| 2024-11-05 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | 開始されました | William Blair | Outperform |
すべてを表示
Upstream Bio Inc (UPB) 最新ニュース
RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com South Africa
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView
Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com - Investing.com Australia
Upstream Bio to present verekitug CRSwNP trial data at AAAAI - Investing.com Nigeria
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Bitget
UPB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Peering Into Upstream Bio Inc's Recent Short Interest - Benzinga
Upstream Bio announces participation in major healthcare conferences - Traders Union
Upstream Bio to Participate in Upcoming March Investor Conferences - Yahoo Finance
Insider Trends: Is Upstream Bio Inc a defensive stockTrade Entry Summary & Community Driven Trade Alerts - baoquankhu1.vn
Can Upstream Bio Inc. ride the EV waveJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru
What are the risks of holding Upstream Bio Inc.2025 Sector Review & Reliable Intraday Trade Plans - mfd.ru
Is Upstream Bio Inc. stock suitable for long term investing2025 Geopolitical Influence & Reliable Price Breakout Alerts - mfd.ru
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio crashes after asthma drug succeeds — with the wrong dose - MSN
S P Trends: Is Upstream Bio Inc forming a bullish divergenceJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56% - MarketBeat
Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth - Yahoo Finance
Can Upstream Bio Inc. stock reach $100 price targetJuly 2025 Institutional & Technical Buy Zone Confirmations - mfd.ru
Exit Recap: Is Upstream Bio Inc. still a buy after recent gainsJuly 2025 Breakouts & Weekly Return Optimization Alerts - mfd.ru
UPB Should I Buy - Intellectia AI
UPB PE Ratio & Valuation, Is UPB Overvalued - Intellectia AI
Growth Recap: Is CNMD stock heavily shortedWeekly Trading Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Upstream Bio (NASDAQ:UPB) Sees Large Volume IncreaseHere's Why - MarketBeat
What is the next catalyst for Upstream Bio Inc.Quarterly Earnings Summary & Real-Time Volume Trigger Notifications - mfd.ru
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns - Bitget
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB) - The Globe and Mail
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Upstream Bio (NASDAQ:UPB) Trading Down 10.3%Time to Sell? - MarketBeat
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data (UPB) - Seeking Alpha
Upstream To Upgrade Verekitug To Phase III After Positive Asthma Results - Citeline News & Insights
Upstream Bio stock tumbles after mixed Phase 2 asthma trial results - Investing.com Canada
Upstream Bio (NASDAQ:UPB) Shares Gap DownHere's Why - MarketBeat
VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial - HCPLive
Will Upstream Bio Inc. benefit from sector rotationGDP Growth & Fast Exit Strategy with Risk Control - mfd.ru
Upstream Bio battered despite positive new verekitug data - The Pharma Letter
Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results - TipRanks
UPB: Verekitug cut severe asthma exacerbations by up to 56% with durable efficacy and infrequent dosing - TradingView
Upstream Bio Faces New Strategic Challenges Amid Latest Developments - timothysykes.com
What’s next for Upstream Bio Inc. stockInflation Watch & Safe Capital Growth Stock Tips - mfd.ru
Upstream Bio Inc (UPB) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):